Personalized Care with DPP4i/SGLT2i Strategy as Initial-Line in the Management of Type 2 Diabetes Mellitus with Cardiovascular Risk: DELPHI Statement. (2024). Cardiology and Cardiovascular Medicine, 8(2), 111-117. https://fortunejournals.org/ojs/index.php/ccm/article/view/16470